MMB-CHMICA

MMB-CHMICA (also known as MMBC and Cimaca) is a synthetic cannabinoid that is an indole-based cannabinoid that has been sold online as a designer drug. It was first identified in 2014 in Japan, although it emerged in Europe in 2015. MMB-CHMICA is believed to have a very high binding affinity for the peripheral CB2 cannabinoid receptor, which could potentially lead to a range of serious health issues.

Chemistry

MMB-CHMICA is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is a derivative of indole and carboxamide.

Pharmacology

MMB-CHMICA acts as a highly potent full agonist of the CB1 receptor. The compound is believed to have a binding affinity for the CB1 receptor which is 1.5 times greater than that of the well-known cannabinoid THC. This high binding affinity is believed to be responsible for the significant number of severe side effects associated with synthetic cannabinoids.

Effects

The effects of MMB-CHMICA are similar to those of other synthetic cannabinoids and include euphoria, relaxation, perception alterations, and appetite increase. However, the compound is also associated with a number of severe side effects including seizures, psychosis, tachycardia, and in some cases, death.

Legal Status

MMB-CHMICA is illegal in many countries including the United States, the United Kingdom, Germany, and Sweden. It is also listed as a Schedule I controlled substance in the United States.

See Also

• Synthetic cannabinoids
• Indole
• Cannabinoid receptor

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia